T1	tradename 0 8	ADCETRIS
T3	nanoparticle 11 31	brentuximab vedotin)
T5	tradename 139 147	ADCETRIS
T7	tradename 211 229	ADCETRIS. ADCETRIS
T9	nanoparticle 232 252	brentuximab vedotin)
T11	routeofadministration 272 283	intravenous
T13	fdaapprovaldate 311 315	2011
T15	adversereaction 325 373	PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML)
T17	tradename 515 523	ADCETRIS
T19	tradename 811 819	ADCETRIS
T21	chemoclass 825 838	CD30-directed
T23	nanoparticle 839 862	antibody-drug conjugate
T25	indication 905 921	Hodgkin lymphoma
T27	indication 1099 1138	Systemic anaplastic large cell lymphoma
T29	routeofadministration 1649 1660	intravenous
T31	frequency 1686 1700	every 3 weeks.
T33	dose 1726 1735	1.8 mg/kg
T35	adversereaction 2213 2235	Peripheral neuropathy:
T37	adversereaction 2321 2356	Anaphylaxis and infusion reactions:
T39	adversereaction 2363 2380	infusion reaction
T41	adversereaction 2418 2429	anaphylaxis
T43	adversereaction 2483 2506	Hematologic toxicities:
T45	tradename 2559 2571	ADCETRIS. 
T47	adversereaction 2611 2635	Grade 3 or 4 neutropenia
T49	adversereaction 2748 2796	Serious infections and opportunistic infections:
T51	adversereaction 2843 2852	bacterial
T53	adversereaction 2854 2880	fungal or viral infections
T55	adversereaction 2889 2910	Tumor lysis syndrome:
T57	adversereaction 2998 3013	Hepatotoxicity:
T59	adversereaction 3058 3089	Serious dermatologic reactions:
T61	adversereaction 3176 3198	Embryo-fetal toxicity:
T63	adversereaction 3432 3443	neutropenia
T65	adversereaction 3445 3474	peripheral sensory neuropathy
T67	adversereaction 3476 3483	fatigue
T69	adversereaction 3485 3491	nausea
T71	adversereaction 3493 3499	anemia
T73	adversereaction 3501 3534	upper respiratory tract infection
T75	adversereaction 3536 3544	diarrhea
T77	adversereaction 3546 3553	pyrexia
T79	adversereaction 3555 3559	rash
T81	adversereaction 3561 3577	thrombocytopenia
T83	adversereaction 3579 3584	cough
T85	adversereaction 3590 3598	vomiting
T87	company 3654 3670	Seattle Genetics
T89	company 3672 3676	Inc.
T91	activeingredient 3958 3988	monomethyl auristatin E (MMAE)
T93	activeingredient 4142 4146	MMAE
T95	adversereaction 4387 4435	PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML)
T97	indication 4468 4484	Hodgkin Lymphoma
T99	indication 4490 4529	Systemic Anaplastic Large Cell Lymphoma
T101	adversereaction 4753 4774	Peripheral Neuropathy
T103	adversereaction 4781 4815	Anaphylaxis and Infusion Reactions
T105	adversereaction 4822 4844	Hematologic Toxicities
T107	adversereaction 4851 4898	Serious Infections and Opportunistic Infections
T109	adversereaction 4905 4925	Tumor Lysis Syndrome
T111	adversereaction 4932 4993	Increased Toxicity in the Presence of Severe Renal Impairment
T113	adversereaction 5000 5075	Increased Toxicity in the Presence of Moderate or Severe Hepatic Impairment
T115	adversereaction 5082 5096	Hepatotoxicity
T117	adversereaction 5103 5145	Progressive Multifocal Leukoencephalopathy
T119	adversereaction 5153 5183	Serious Dermatologic Reactions
T121	adversereaction 5191 5212	Embryo-Fetal Toxicity
T123	tradename 5350 5359	ADCETRIS 
T125	tradename 5374 5382	ADCETRIS
T127	indication 5800 5816	Hodgkin Lymphoma
T129	indication 5823 5862	Systemic Anaplastic Large Cell Lymphoma
T131	tradename 6272 6280	ADCETRIS
T133	indication 6378 6394	Hodgkin Lymphoma
T135	tradename 6396 6404	ADCETRIS
T137	nanoparticle 6406 6426	brentuximab vedotin)
T139	indication 6471 6492	Hodgkin lymphoma (HL)
T141	indication 7006 7045	Systemic Anaplastic Large Cell Lymphoma
T143	tradename 7047 7055	ADCETRIS
T145	indication 7100 7147	systemic anaplastic large cell lymphoma (sALCL)
T147	tradename 7627 7635	ADCETRIS
T149	routeofadministration 7642 7653	intravenous
T151	frequency 7679 7692	every 3 weeks
T153	tradename 7817 7825	ADCETRIS
T155	dose 7896 7918	1.8 mg/kg up to 180 mg
T157	dose 8043 8065	1.8 mg/kg up to 180 mg
T159	dose 8203 8225	1.2 mg/kg up to 120 mg
T161	dose 8512 8522	1.2 mg/kg.
T163	tradename 8559 8567	ADCETRIS
T165	tradename 8620 8628	ADCETRIS
T167	tradename 8981 8989	ADCETRIS
T169	dose 8993 9003	1.2 mg/kg.
T171	tradename 9085 9093	ADCETRIS
T173	routeofadministration 9100 9111	intravenous
T175	tradename 9139 9147	ADCETRIS
T177	indication 9286 9296	anticancer
T179	tradename 9595 9603	ADCETRIS
T181	nanoparticle 9704 9724	brentuximab vedotin.
T183	tradename 10382 10390	ADCETRIS
T185	nanoparticle 10671 10691	brentuximab vedotin.
T187	tradename 10770 10778	ADCETRIS
T189	dose 10987 10992	50 mg
T191	nanoparticle 10996 11015	brentuximab vedotin
T193	tradename 11159 11168	 ADCETRIS
T195	adversereaction 11361 11382	Peripheral Neuropathy
T197	tradename 11384 11392	ADCETRIS
T199	adversereaction 11412 11433	peripheral neuropathy
T201	adversereaction 11476 11503	peripheral motor neuropathy
T203	tradename 11531 11547	ADCETRIS-induced
T205	adversereaction 11548 11569	peripheral neuropathy
T207	indication 11592 11594	HL
T209	indication 11599 11604	sALCL
T211	adversereaction 11663 11674	neuropathy.
T213	adversereaction 11812 11822	neuropathy
T215	adversereaction 11841 11851	neuropathy
T217	adversereaction 11925 11935	neuropathy
T219	adversereaction 11945 11957	hypoesthesia
T221	adversereaction 11959 11972	hyperesthesia
T223	adversereaction 11974 11985	paresthesia
T225	adversereaction 11987 11997	discomfort
T227	adversereaction 11999 12018	a burning sensation
T229	adversereaction 12020 12036	neuropathic pain
T231	adversereaction 12041 12050	weakness.
T233	adversereaction 12092 12113	peripheral neuropathy
T235	tradename 12173 12181	ADCETRIS
T237	adversereaction 12218 12279	Anaphylaxis and Infusion Reactions Infusion-related reactions
T239	adversereaction 12291 12302	anaphylaxis
T241	tradename 12323 12335	ADCETRIS. 
T243	adversereaction 12374 12385	anaphylaxis
T245	tradename 12452 12460	ADCETRIS
T247	adversereaction 12513 12538	infusion-related reaction
T249	co-administereddrug 12771 12784	acetaminophen
T251	co-administereddrug 12789 12802	antihistamine
T253	co-administereddrug 12810 12825	corticosteroid.
T255	adversereaction 12832 12854	Hematologic Toxicities
T257	adversereaction 12890 12901	neutropenia
T259	adversereaction 12906 12941	Grade 3 or Grade 4 thrombocytopenia
T261	adversereaction 12945 12951	anemia
T263	tradename 12967 12979	ADCETRIS. 
T265	adversereaction 12979 12998	Febrile neutropenia
T267	tradename 13037 13049	ADCETRIS. 
T269	tradename 13113 13121	ADCETRIS
T271	adversereaction 13190 13215	Grade 3 or 4 neutropenia.
T273	adversereaction 13249 13273	Grade 3 or 4 neutropenia
T275	tradename 13372 13380	ADCETRIS
T277	adversereaction 13424 13471	Serious Infections and Opportunistic Infections
T279	adversereaction 13473 13520	Serious infections and opportunistic infections
T281	adversereaction 13529 13538	pneumonia
T283	adversereaction 13540 13550	bacteremia
T285	adversereaction 13556 13578	sepsis or septic shock
T287	tradename 13650 13662	ADCETRIS. 
T289	adversereaction 13746 13755	bacterial
T291	adversereaction 13757 13763	fungal
T293	adversereaction 13765 13785	or viral infections.
T295	adversereaction 13792 13812	Tumor Lysis Syndrome
T297	adversereaction 13906 13927	tumor lysis syndrome.
T299	adversereaction 13982 14043	Increased Toxicity in the Presence of Severe Renal Impairment
T301	adversereaction 14101 14107	deaths
T303	activeingredient 14226 14230	MMAE
T305	tradename 14405 14413	ADCETRIS
T307	adversereaction 14546 14621	Increased Toxicity in the Presence of Moderate or Severe Hepatic Impairment
T309	adversereaction 14679 14685	deaths
T311	tradename 14823 14831	ADCETRIS
T313	adversereaction 14964 14978	Hepatotoxicity
T315	adversereaction 14997 15011	hepatotoxicity
T317	adversereaction 15023 15037	fatal outcomes
T319	tradename 15075 15087	ADCETRIS. 
T321	tradename 15238 15246	ADCETRIS
T323	tradename 15256 15264	ADCETRIS
T325	adversereaction 15486 15500	hepatotoxicity
T327	tradename 15560 15572	ADCETRIS.  
T329	adversereaction 15576 15618	Progressive Multifocal Leukoencephalopathy
T331	adversereaction 15652 15655	PML
T333	adversereaction 15660 15665	death
T335	tradename 15687 15703	ADCETRIS-treated
T337	tradename 15730 15738	ADCETRIS
T339	adversereaction 15893 15896	PML
T341	tradename 16004 16012	ADCETRIS
T343	adversereaction 16046 16049	PML
T345	tradename 16066 16074	ADCETRIS
T347	adversereaction 16100 16103	PML
T349	adversereaction 16125 16155	Serious Dermatologic Reactions
T351	adversereaction 16157 16187	Stevens-Johnson syndrome (SJS)
T353	adversereaction 16192 16224	toxic epidermal necrolysis (TEN)
T355	adversereaction 16236 16250	fatal outcomes
T357	tradename 16276 16285	ADCETRIS.
T359	adversereaction 16290 16293	SJS
T361	adversereaction 16297 16300	TEN
T363	tradename 16321 16329	ADCETRIS
T365	adversereaction 16381 16402	Embryo-Fetal Toxicity
T367	tradename 16457 16465	ADCETRIS
T369	tradename 16554 16562	ADCETRIS
T371	nanoparticle 16625 16644	Brentuximab vedotin
T373	adversereaction 16652 16675	embryo-fetal toxicities
T375	adversereaction 16701 16727	decreased embryo viability
T377	adversereaction 16732 16751	fetal malformations
T379	adversereaction 17247 17268	Peripheral neuropathy
T381	adversereaction 17307 17341	Anaphylaxis and Infusion Reactions
T383	adversereaction 17380 17402	Hematologic Toxicities
T385	adversereaction 17448 17495	Serious Infections and Opportunistic Infections
T387	adversereaction 17534 17554	Tumor Lysis Syndrome
T389	adversereaction 17593 17654	Increased Toxicity in the Presence of Severe Renal Impairment
T391	adversereaction 17693 17768	Increased Toxicity in the Presence of Moderate or Severe Hepatic Impairment
T393	adversereaction 17807 17821	Hepatotoxicity
T395	adversereaction 17860 17902	Progressive Multifocal Leukoencephalopathy
T397	adversereaction 17941 17971	Serious Dermatologic Reactions
T399	adversereaction 18011 18032	Embryo-Fetal Toxicity
T401	tradename 18366 18374	ADCETRIS
T403	adversereaction 18541 18552	neutropenia
T405	adversereaction 18554 18583	peripheral sensory neuropathy
T407	adversereaction 18585 18592	fatigue
T409	adversereaction 18594 18600	nausea
T411	adversereaction 18602 18608	anemia
T413	adversereaction 18610 18643	upper respiratory tract infection
T415	adversereaction 18645 18653	diarrhea
T417	adversereaction 18655 18662	pyrexia
T419	adversereaction 18664 18668	rash
T421	adversereaction 18670 18686	thrombocytopenia
T423	adversereaction 18688 18693	cough
T425	adversereaction 18699 18708	vomiting.
T427	indication 18915 18931	Hodgkin Lymphoma
T429	tradename 18933 18941	ADCETRIS
T431	indication 18975 18977	HL
T433	dose 19065 19074	1.8 mg/kg
T435	routeofadministration 19075 19088	intravenously
T437	frequency 19089 19103	every 3 weeks.
T439	duration 19139 19147	27 weeks
T441	duration 19156 19170	3 to 56 weeks)
T443	adversereaction 19282 19293	neutropenia
T445	adversereaction 19295 19324	peripheral sensory neuropathy
T447	adversereaction 19326 19333	fatigue
T449	adversereaction 19335 19368	upper respiratory tract infection
T451	adversereaction 19370 19376	nausea
T453	adversereaction 19378 19386	diarrhea
T455	adversereaction 19388 19394	anemia
T457	adversereaction 19396 19403	pyrexia
T459	adversereaction 19405 19421	thrombocytopenia
T461	adversereaction 19423 19427	rash
T463	adversereaction 19429 19443	abdominal pain
T465	adversereaction 19445 19450	cough
T467	adversereaction 19456 19465	vomiting.
T469	tradename 19467 19468	 
T471	adversereaction 19468 19486	Pulmonary Toxicity
T473	indication 19531 19533	HL
T475	tradename 19547 19555	ADCETRIS
T477	adversereaction 19632 19650	pulmonary toxicity
T479	adversereaction 19792 19797	cough
T481	adversereaction 19802 19810	dyspnea.
T483	tradename 20004 20012	ADCETRIS
T485	indication 20092 20131	Systemic Anaplastic Large Cell Lymphoma
T487	tradename 20133 20141	ADCETRIS
T489	indication 20174 20179	sALCL
T491	dose 20267 20276	1.8 mg/kg
T493	routeofadministration 20277 20290	intravenously
T495	frequency 20291 20305	every 3 weeks.
T497	duration 20341 20349	24 weeks
T499	duration 20358 20372	3 to 56 weeks)
T501	adversereaction 20484 20495	neutropenia
T503	adversereaction 20497 20503	anemia
T505	adversereaction 20505 20534	peripheral sensory neuropathy
T507	adversereaction 20536 20543	fatigue
T509	adversereaction 20545 20551	nausea
T511	adversereaction 20553 20560	pyrexia
T513	adversereaction 20568 20576	diarrhea
T515	adversereaction 20582 20587	pain.
T517	adversereaction 20856 20868	Neutropenia*
T519	adversereaction 20870 20877	Anemia*
T521	adversereaction 20879 20896	Thrombocytopenia*
T523	adversereaction 20900 20915	Lymphadenopathy
T525	adversereaction 20945 20963	Peripheral sensory
T527	adversereaction 20971 20981	neuropathy
T529	adversereaction 20985 21001	Peripheral motor
T531	adversereaction 21008 21037	neuropathy Headache Dizziness
T533	adversereaction 21094 21101	Fatigue
T535	adversereaction 21103 21110	Pyrexia
T537	adversereaction 21112 21118	Chills
T539	adversereaction 21120 21124	Pain
T541	tradename 21126 21127	 
T543	adversereaction 21127 21143	Edema peripheral
T545	adversereaction 21173 21206	Upper respiratory tract infection
T547	adversereaction 21236 21242	Nausea
T549	adversereaction 21244 21252	Diarrhea
T551	adversereaction 21254 21268	Abdominal pain
T553	adversereaction 21270 21278	Vomiting
T555	adversereaction 21280 21292	Constipation
T557	adversereaction 21334 21338	Rash
T559	adversereaction 21340 21348	Pruritus
T561	adversereaction 21350 21358	Alopecia
T563	adversereaction 21360 21372	Night sweats
T565	adversereaction 21374 21382	Dry skin
T567	tradename 21693 21694	 
T569	indication 21694 21696	HL
T571	indication 21726 21731	sALCL
T573	adversereaction 21905 21912	Dyspnea
T575	tradename 21927 21928	 
T577	adversereaction 21928 21946	Oropharyngeal pain
T579	adversereaction 22011 22021	Arthralgia
T581	adversereaction 22035 22042	Myalgia
T583	adversereaction 22057 22066	Back pain
T585	adversereaction 22081 22098	Pain in extremity
T587	tradename 22114 22115	 
T589	adversereaction 22115 22128	Muscle spasms
T591	adversereaction 22166 22174	Insomnia
T593	adversereaction 22189 22196	Anxiety
T595	adversereaction 22247 22265	Decreased appetite
T597	adversereaction 22295 22311	Weight decreased
T599	adversereaction 22385 22403	Infusion reactions
T601	adversereaction 22418 22429	anaphylaxis
T603	adversereaction 22492 22518	infusion-related reactions
T605	adversereaction 22573 22599	infusion-related reactions
T607	adversereaction 22702 22728	infusion-related reactions
T609	adversereaction 22734 22740	chills
T611	adversereaction 22747 22753	nausea
T613	adversereaction 22760 22767	dyspnea
T615	adversereaction 22774 22782	pruritus
T617	adversereaction 22789 22796	pyrexia
T619	adversereaction 22807 22812	cough
T621	tradename 22966 22977	ADCETRIS. 
T623	indication 23048 23050	HL
T625	adversereaction 23059 23086	peripheral motor neuropathy
T627	adversereaction 23093 23107	abdominal pain
T629	adversereaction 23114 23132	pulmonary embolism
T631	adversereaction 23139 23150	pneumonitis
T633	adversereaction 23157 23169	pneumothorax
T635	adversereaction 23176 23190	pyelonephritis
T637	adversereaction 23201 23208	pyrexia
T639	indication 23288 23293	sALCL
T641	adversereaction 23299 23311	septic shock
T643	adversereaction 23318 23345	supraventricular arrhythmia
T645	adversereaction 23352 23369	pain in extremity
T647	adversereaction 23380 23403	urinary tract infection
T649	adversereaction 23470 23473	PML
T651	adversereaction 23475 23499	Stevens-Johnson syndrome
T653	adversereaction 23505 23526	tumor lysis syndrome.
T655	adversereaction 23624 23635	neutropenia
T657	adversereaction 23646 23675	peripheral sensory neuropathy
T659	indication 23895 23897	HL
T661	indication 23901 23906	sALCL
T663	adversereaction 23912 23941	peripheral sensory neuropathy
T665	adversereaction 23951 23978	peripheral motor neuropathy
T667	tradename 24099 24111	ADCETRIS. 
T669	adversereaction 24352 24371	febrile neutropenia
T671	adversereaction 24436 24450	hepatotoxicity
T673	adversereaction 24501 24504	PML
T675	adversereaction 24565 24605	 infections and opportunistic infections
T677	adversereaction 24681 24695	hyperglycemia.
T679	adversereaction 24725 24737	Pancreatitis
T681	adversereaction 24899 24925	Toxic epidermal necrolysis
T683	indication 25027 25029	HL
T685	indication 25034 25039	sALCL
T687	nanoparticle 25120 25139	brentuximab vedotin
T689	frequency 25140 25153	every 3 weeks
T691	nanoparticle 25519 25538	brentuximab vedotin
T693	adversereaction 25813 25839	infusion related reactions
T695	tradename 26585 26593	ADCETRIS
T697	activeingredient 26716 26746	monomethyl auristatin E (MMAE)
T699	activeingredient 26821 26825	MMAE
T701	tradename 26926 26936	ADCETRIS 
T703	activeingredient 26964 26968	MMAE
T705	tradename 27061 27069	ADCETRIS
T707	activeingredient 27138 27142	MMAE
T709	tradename 27238 27246	ADCETRIS
T711	tradename 27320 27328	ADCETRIS
T713	activeingredient 27389 27393	MMAE
T715	tradename 27455 27463	ADCETRIS
T717	activeingredient 27510 27515	MMAE.
T719	tradename 27579 27587	ADCETRIS
T721	tradename 27655 27663	ADCETRIS
T723	tradename 27701 27709	ADCETRIS
T725	activeingredient 27770 27774	MMAE
T727	tradename 27883 27891	ADCETRIS
T729	tradename 28159 28167	ADCETRIS
T731	tradename 28255 28263	ADCETRIS
T733	nanoparticle 28326 28345	Brentuximab vedotin
T735	adversereaction 28353 28376	embryo-fetal toxicities
T737	indication 28490 28492	HL
T739	indication 28497 28503	sALCL.
T741	routeofadministration 28757 28768	intravenous
T743	dose 28778 28781	0.3
T745	dose 28783 28784	1
T747	dose 28786 28787	3
T749	dose 28789 28800	or 10 mg/kg
T751	nanoparticle 28801 28820	brentuximab vedotin
T753	adversereaction 28910 28933	embryo-fetal toxicities
T755	dose 28975 28989	3 and 10 mg/kg
T757	nanoparticle 29247 29266	brentuximab vedotin
T759	dose 29275 29282	3 mg/kg
T761	indication 29335 29337	HL
T763	indication 29341 29346	sALCL
T765	dose 29384 29393	1.8 mg/kg
T767	frequency 29394 29412	every three weeks.
T769	nanoparticle 29460 29479	brentuximab vedotin
T771	tradename 29638 29646	ADCETRIS
T773	tradename 29847 29855	ADCETRIS
T775	tradename 29930 29938	ADCETRIS
T777	tradename 30115 30123	ADCETRIS
T779	tradename 30347 30355	ADCETRIS
T781	activeingredient 30495 30526	monomethyl auristatin E (MMAE).
T783	nanoparticle 30563 30582	brentuximab vedotin
T785	activeingredient 30587 30591	MMAE
T787	dose 30635 30644	1.2 mg/kg
T789	tradename 30648 30656	ADCETRIS
T791	activeingredient 30990 30994	MMAE
T793	tradename 31009 31018	ADCETRIS)
T795	activeingredient 31157 31161	MMAE
T797	tradename 31360 31368	ADCETRIS
T799	activeingredient 31501 31506	MMAE.
T801	nanoparticle 31543 31562	brentuximab vedotin
T803	activeingredient 31567 31571	MMAE
T805	tradename 31628 31636	ADCETRIS
T807	activeingredient 31967 31971	MMAE
T809	tradename 32158 32167	ADCETRIS.
T811	tradename 32348 32357	 ADCETRIS
T813	nanoparticle 32359 32379	brentuximab vedotin)
T815	chemoclass 32385 32398	CD30-directed
T817	nanoparticle 32399 32428	antibody-drug conjugate (ADC)
T819	chemoclass 32530 32558	microtubule disrupting agent
T821	activeingredient 32559 32563	MMAE
T823	activeingredient 32625 32629	MMAE
T825	nanoparticle 32641 32660	Brentuximab vedotin
T827	molecularweight 32700 32708	153 kDa.
T829	activeingredient 32739 32743	MMAE
T831	nanoparticle 32786 32805	Brentuximab vedotin
T833	tradename 33031 33039	ADCETRIS
T835	nanoparticle 33041 33061	brentuximab vedotin)
T837	inactiveingredient 33236 33241	Water
T839	nanoparticle 33292 33311	brentuximab vedotin
T841	inactiveingredient 33370 33389	trehalose dihydrate
T843	inactiveingredient 33401 33425	sodium citrate dihydrate
T845	inactiveingredient 33438 33461	citric acid monohydrate
T847	inactiveingredient 33478 33492	polysorbate 80
T849	inactiveingredient 33497 33502	water
T851	nanoparticle 33602 33621	Brentuximab vedotin
T853	nanoparticle 33628 33632	ADC.
T855	activeingredient 33711 33715	MMAE
T857	chemoclass 33722 33751	microtubule disrupting agent.
T859	activeingredient 33754 33758	MMAE
T861	indication 33847 33857	anticancer
T863	tradename 33870 33878	ADCETRIS
T865	nanoparticle 33908 33911	ADC
T867	nanoparticle 33973 33979	ADC-CD
T869	activeingredient 34010 34014	MMAE
T871	activeingredient 34054 34058	MMAE
T873	nanoparticle 34263 34282	brentuximab vedotin
T875	dose 34284 34294	1.8 mg/kg)
T877	nanoparticle 34455 34474	brentuximab vedotin
T879	nanoparticle 34737 34756	brentuximab vedotin
T881	nanoparticle 34923 34926	ADC
T883	activeingredient 34928 34932	MMAE
T885	nanoparticle 35032 35036	ADC.
T887	nanoparticle 35066 35069	ADC
T889	activeingredient 35074 35078	MMAE
T891	nanoparticle 35139 35142	ADC
T893	nanoparticle 35228 35231	ADC
T895	plasmahalflife 35309 35321	4 to 6 days.
T897	dose 35375 35392	1.2 to 2.7 mg/kg.
T899	nanoparticle 35413 35416	ADC
T901	tmax 35430 35444	within 21 days
T903	frequency 35450 35462	every 3-week
T905	tradename 35473 35481	ADCETRIS
T907	nanoparticle 35563 35566	ADC
T909	frequency 35607 35619	every 3-week
T911	activeingredient 35669 35673	MMAE
T913	tmax 35700 35712	1 to 3 days.
T915	nanoparticle 35729 35732	ADC
T917	activeingredient 35750 35754	MMAE
T919	tmax 35768 35782	within 21 days
T921	tmax 35788 35800	every 3 week
T923	tradename 35811 35820	ADCETRIS.
T925	activeingredient 35822 35826	MMAE
T927	tradename 35880 35888	ADCETRIS
T929	activeingredient 36028 36032	MMAE
T931	activeingredient 36086 36090	MMAE
T933	activeingredient 36178 36182	MMAE
T935	volumeofdistribution 36322 36335	6&#x2013;10 L
T937	nanoparticle 36340 36344	ADC.
T939	activeingredient 36430 36434	MMAE
T941	activeingredient 36449 36468	brentuximab vedotin
T943	activeingredient 36519 36523	MMAE
T945	activeingredient 36648 36652	MMAE
T947	activeingredient 36701 36705	MMAE
T949	activeingredient 36801 36805	MMAE
T951	activeingredient 36870 36874	MMAE
T953	nanoparticle 36927 36931	ADC.
T955	dose 37003 37012	1.8 mg/kg
T957	tradename 37016 37025	ADCETRIS.
T959	activeingredient 37057 37061	MMAE
T961	nanoparticle 37090 37093	ADC
T963	tradename 37104 37112	ADCETRIS
T965	activeingredient 37200 37204	MMAE
T967	activeingredient 37284 37288	MMAE
T969	nanoparticle 37613 37633	brentuximab vedotin.
T971	nanoparticle 37751 37770	brentuximab vedotin
T973	activeingredient 37794 37799	MMAE)
T975	activeingredient 37826 37830	MMAE
T977	activeingredient 37980 37984	MMAE
T979	chemoclass 37990 38019	microtubule disrupting agent.
T981	activeingredient 38022 38026	MMAE
T983	nanoparticle 38174 38193	brentuximab vedotin
T985	activeingredient 38197 38201	MMAE
T987	nanoparticle 38312 38331	brentuximab vedotin
T989	duration 38390 38396	4-week
T991	dose 38454 38457	0.5
T993	dose 38459 38472	5 or 10 mg/kg
T995	nanoparticle 38473 38492	brentuximab vedotin
T997	dose 38648 38662	5 and 10 mg/kg
T999	nanoparticle 38666 38686	brentuximab vedotin.
T1001	dose 38761 38770	1.8 mg/kg
T1003	indication 38837 38853	Hodgkin Lymphoma
T1005	tradename 38871 38879	ADCETRIS
T1007	indication 38897 38899	HL
T1009	dose 39060 39069	1.8 mg/kg
T1011	tradename 39073 39081	ADCETRIS
T1013	routeofadministration 39082 39095	intravenously
T1015	frequency 39112 39126	every 3 weeks.
T1017	indication 39933 39949	Hodgkin Lymphoma
T1019	indication 40240 40279	Systemic Anaplastic Large Cell Lymphoma
T1021	tradename 40297 40305	ADCETRIS
T1023	indication 40332 40337	sALCL
T1025	indication 40449 40454	sALCL
T1027	dose 40534 40543	1.8 mg/kg
T1029	tradename 40547 40555	ADCETRIS
T1031	routeofadministration 40569 40582	intravenously
T1033	frequency 40599 40613	every 3 weeks.
T1035	indication 41639 41678	Systemic Anaplastic Large Cell Lymphoma
T1037	tradename 42156 42164	ADCETRIS
T1039	nanoparticle 42166 42186	brentuximab vedotin)
T1041	nanoparticle 42358 42378	brentuximab vedotin.
T1043	tradename 42510 42518	ADCETRIS
T1045	adversereaction 42638 42659	Peripheral neuropathy
T1047	tradename 42682 42690	ADCETRIS
T1049	adversereaction 42703 42725	peripheral neuropathy.
T1051	adversereaction 42898 42915	Fever/Neutropenia
T1053	adversereaction 42976 42981	fever
T1055	adversereaction 43137 43155	Infusion reactions
T1057	adversereaction 43258 43276	infusion reactions
T1059	adversereaction 43397 43411	Hepatotoxicity
T1061	adversereaction 43466 43478	liver injury
T1063	adversereaction 43606 43648	Progressive multifocal leukoencephalopathy
T1065	tradename 43678 43686	ADCETRIS
T1067	adversereaction 44116 44128	Pancreatitis
T1069	tradename 44277 44286	 ADCETRIS
T1071	tradename 44334 44342	ADCETRIS
T1073	tradename 44502 44510	ADCETRIS
T1075	company 44575 44591	Seattle Genetics
T1077	company 44593 44597	Inc.
T1079	tradename 44650 44658	ADCETRIS
T1081	company 44660 44676	Seattle Genetics
T1083	company 44714 44730	Seattle Genetics
T1085	company 44732 44736	Inc.
